Survey of Ophthalmology
Volume 44 , Pages S147-S153 , January 2000

Dose-Response Evaluation of the Ocular Hypotensive Effect of Brinzolamide Ophthalmic Suspension (Azopt®)

  • Lewis H. Silver, PhD

      Affiliations

    • Alcon Research, Ltd., Fort Worth, TX, USA
    • Corresponding Author InformationReprint address: Lewis H. Silver, PhD, Senior Director, Clinical Science, Ophthalmic Products, Alcon Laboratories, Inc., 6201 South Freeway, R5-10, Fort Worth, TX 76134-2099
    • ,
  • the Brinzolamide Dose-Response Study Group

      Affiliations

    • Alcon Research, Ltd., Fort Worth, TX, USA

References 

  1. Dean T, May J, Chen HH, et al.  Brinzolamide (AL-4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbit and cynomolgus monkey (abstract). Invest Ophthalmol Vis Sci. 1997;38(suppl):S813
  2. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Arch Ophthalmol. 1977;95:1378–1382
  3. Kitazawa Y, Azuma I, Iwata K, et al.  Dorzolamide, a typical carbonic anhydrase inhibitor (a two-week dose response study in patients with glaucoma or ocular hypertension). J Glaucoma. 1994;3:275–279
  4. Lippa EA, Carlson L-E, Eriksson L-O, et al.  Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110:495–499
  5. Maus TL, Larsson L-I, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45–49
  6. Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg. 1995;26:233–236
  7. Pfeiffer N, Hennekes R, Lippa E, et al.  A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients. Br J Ophthalmol. 1990;74:405–408
  8. Silver L, Brinzolamide Comfort Study Group . The ocular comfort of brinzolamide 1.0% ophthalmic suspension compared to dorzolamide 2.0% ophthalmic solution (results from two multicenter comfort studies). Surv Ophthalmol. 2000;44(suppl 2):S141–S145
  9. Strahlman E, Tipping R, Vogel R, Dorzolamide Dose-Response Study Group . A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol. 1996;122:183–194

PII: S0039-6257(99)00110-1

Survey of Ophthalmology
Volume 44 , Pages S147-S153 , January 2000

Article Tools